Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Expands By 921.9%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 191,100 shares, a growth of 921.9% from the March 31st total of 18,700 shares. Based on an average daily volume of 210,400 shares, the days-to-cover ratio is presently 0.9 days. Currently, 7.6% of the company’s stock are sold short.

Vivos Therapeutics Stock Performance

Shares of VVOS stock traded down $0.10 on Thursday, hitting $2.47. The stock had a trading volume of 45,277 shares, compared to its average volume of 186,761. The firm has a market capitalization of $7.36 million, a price-to-earnings ratio of -0.23 and a beta of 7.94. The stock’s 50 day moving average is $4.16 and its 200-day moving average is $6.80. Vivos Therapeutics has a 52-week low of $2.37 and a 52-week high of $48.79.

Vivos Therapeutics (NASDAQ:VVOS) last announced its earnings results on Thursday, March 28th. The company reported ($3.05) earnings per share for the quarter. The firm had revenue of $3.25 million during the quarter. Vivos Therapeutics had a negative net margin of 98.42% and a negative return on equity of 665.17%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Vivos Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned about 4.29% of Vivos Therapeutics at the end of the most recent reporting period. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.